文献速递心脑血管急症

PCSK9抑制剂与依折麦布联合或不联合他汀治疗降低心血管风险:系统评价与网络Meta分析

PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
PubMed 文献 · BMJ · 2022-05-04
一句话结论在高心血管风险或极高心血管风险成人中,最大耐受他汀基础上加用依折麦布或PCSK9抑制剂可能减少非致死性心肌梗死和卒中,中低风险人群获益甚微。

该系统评价与网络Meta分析纳入14项随机对照试验、共83 660名使用他汀的成人,比较依折麦布和PCSK9抑制剂对心血管结局的影响。结果显示,他汀加依折麦布降低心肌梗死(RR 0.87,95%CI 0.80-0.94)和卒中(RR 0.82,0.71-0.96),他汀加PCSK9抑制剂降低心肌梗死(RR 0.81,0.76-0.87)和卒中(RR 0.74,0.64-0.85),但两者均未显著降低全因死亡或心血管死亡。在极高心血管风险成人中,加用PCSK9抑制剂可能减少心肌梗死(每1000人16例)和卒中(每1000人21例)(中至高确定性);加用依折麦布可能减少卒中(每1000人14例),但心肌梗死减少(每1000人11例)未达最小重要差异。中低风险人群获益甚微或无获益。

要点

  • 在极高心血管风险成人中,他汀加PCSK9抑制剂可能减少心肌梗死(每1000人16例)和卒中(每1000人21例)(中至高确定性)。
  • 在极高心血管风险成人中,他汀加依折麦布可能减少卒中(每1000人14例),但心肌梗死减少(每1000人11例)未达最小重要差异(中等确定性)。
  • 在高心血管风险成人中,他汀加PCSK9抑制剂可能减少心肌梗死(每1000人12例)和卒中(每1000人16例)(中等确定性)。
  • 在高心血管风险成人中,他汀加依折麦布可能减少卒中(每1000人11例),但心肌梗死减少未达最小重要差异(每1000人8例)(中等确定性)。
  • 在中、低心血管风险成人中,他汀加PCSK9抑制剂或依折麦布对心肌梗死和卒中获益甚微或无获益。

适用人群与场景

  • 使用最大耐受他汀治疗或他汀不耐受的成人,来自14项随机对照试验共83 660名参与者。
  • 按心血管风险分层:极高心血管风险、高心血管风险、中低心血管风险;PREDICT风险计算器用于评估一级和二级预防的心血管风险。
  • 他汀不耐受患者中效应一致。

诊断标准与关键阈值

  • 纳入标准:依折麦布和PCSK9抑制剂的随机对照试验,样本量≥500例,随访≥6个月。
  • 最小重要差异(MID):心肌梗死每1000人12例,卒中每1000人10例,由指南专家组和系统评价作者确定。

研究设计与关键结果

  • 研究设计:系统评价与网络Meta分析,纳入14项随机对照试验、83 660名使用他汀的成人,采用频率学固定效应网络Meta分析和GRADE分级评估证据确定性。
  • 他汀加依折麦布 vs 他汀:心肌梗死RR 0.87(95%CI 0.80-0.94),卒中RR 0.82(0.71-0.96),全因死亡RR 0.99(0.92-1.06),心血管死亡RR 0.97(0.87-1.09)。
  • 他汀加PCSK9抑制剂 vs 他汀:心肌梗死RR 0.81(95%CI 0.76-0.87),卒中RR 0.74(0.64-0.85),全因死亡RR 0.95(0.87-1.03),心血管死亡RR 0.95(0.87-1.03)。
  • 极高心血管风险成人:他汀加PCSK9抑制剂可能减少心肌梗死(每1000人16例)和卒中(每1000人21例)(中至高确定性);他汀加依折麦布可能减少卒中(每1000人14例),心肌梗死减少(每1000人11例)未达MID(中等确定性)。
  • 极高心血管风险成人:PCSK9抑制剂加他汀基础上加依折麦布可能减少卒中(每1000人11例),心肌梗死减少(每1000人9例)未达MID(低确定性);依折麦布加他汀基础上加PCSK9抑制剂可能减少心肌梗死(每1000人14例)和卒中(每1000人17例)(低确定性)。
  • 高心血管风险成人:他汀加PCSK9抑制剂可能减少心肌梗死(每1000人12例)和卒中(每1000人16例)(中等确定性);他汀加依折麦布可能减少卒中(每1000人11例),心肌梗死减少(每1000人8例)未达MID(中等确定性)。
  • 高心血管风险成人:PCSK9抑制剂加他汀基础上加依折麦布未使结局获益超过MID;依折麦布加他汀基础上加PCSK9抑制剂可能减少卒中(每1000人13例)。
  • 中、低心血管风险成人:他汀加PCSK9抑制剂或依折麦布对心肌梗死和卒中获益甚微或无获益。

证据类型、等级与局限

  • 证据类型:系统评价与网络Meta分析,采用GRADE分级评估证据确定性(中至高、中等、低确定性)。

对床旁实践的改变

  • 对于极高心血管风险或高心血管风险、正在接受最大耐受他汀治疗或他汀不耐受的成人,加用依折麦布或PCSK9抑制剂可能减少非致死性心肌梗死和卒中。
  • 对于中、低心血管风险成人,加用依折麦布或PCSK9抑制剂对心肌梗死和卒中获益甚微或无获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To compare the impact of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on cardiovascular outcomes in adults taking maximally tolerated statin therapy or who are statin intolerant.

DESIGN: Network meta-analysis.

DATA SOURCES: Medline, EMBASE, and Cochrane Library up to 31 December 2020.

ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials of ezetimibe and PCSK9 inhibitors with ≥500 patients and follow-up of ≥6 months.

MAIN OUTCOME MEASURES: We performed frequentist fixed-effects network meta-analysis and GRADE (grading of recommendations, assessment, development, and evaluation) to assess certainty of evidence. Results included relative risks (RR) and absolute risks per 1000 patients treated for five years for non-fatal myocardial infarction (MI), non-fatal stroke, all-cause mortality, and cardiovascular mortality. We estimated absolute risk differences assuming constant RR (estimated from network meta-analysis) across different baseline therapies and cardiovascular risk thresholds; the PREDICT risk calculator estimated cardiovascular risk in primary and secondary prevention. Patients were categorised at low to very high cardiovascular risk. A guideline panel and systematic review authors established the minimal important differences (MID) of 12 per 1000 for MI and 10 per 1000 for stroke.

RESULTS: We identified 14 trials assessing ezetimibe and PCSK9 inhibitors among 83 660 adults using statins. Adding ezetimibe to statins reduced MI (RR 0.87 (95% confidence interval 0.80 to 0.94)) and stroke (RR 0.82 (0.71 to 0.96)) but not all-cause mortality (RR 0.99 (0.92 to 1.06)) or cardiovascular mortality (RR 0.97 (0.87 to 1.09)). Similarly, adding PCSK9 inhibitor to statins reduced MI (0.81 (0.76 to 0.87)) and stroke (0.74 (0.64 to 0.85)) but not all-cause (0.95 (0.87 to 1.03)) or cardiovascular mortality (0.95 (0.87 to 1.03)). Among adults with very high cardiovascular risk, adding PCSK9 inhibitor was likely to reduce MI (16 per 1000) and stroke (21 per 1000) (moderate to high certainty); whereas adding ezetimibe was likely to reduce stroke (14 per 1000), but the reduction of MI (11 per 1000) (moderate certainty) did not reach MID. Adding ezetimibe to PCSK9 inhibitor and statin may reduce stroke (11 per 1000), but the reduction of MI (9 per 1000) (low certainty) did not reach MID. Adding PCSK9 inhibitors to statins and ezetimibe may reduce MI (14 per 1000) and stroke (17 per 1000) (low certainty). Among adults with high cardiovascular risk, adding PCSK9 inhibitor probably reduced MI (12 per 1000) and stroke (16 per 1000) (moderate certainty); adding ezetimibe probably reduced stroke (11 per 1000), but the reduction in MI did not achieve MID (8 per 1000) (moderate certainty). Adding ezetimibe to PCSK9 inhibitor and statins did not reduce outcomes beyond MID, while adding PCSK9 inhibitor to ezetimibe and statins may reduce stroke (13 per 1000). These effects were consistent in statin-intolerant patients. Among moderate and low cardiovascular risk groups, adding PCSK9 inhibitor or ezetimibe to statins yielded little or no benefit for MI and stroke.

CONCLUSIONS: Ezetimibe or PCSK9 inhibitors may reduce non-fatal MI and stroke in adults at very high or high cardiovascular risk who are receiving maximally tolerated statin therapy or are statin-intolerant, but not in those with moderate and low cardiovascular risk.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Khan SU, Yedlapati SH, Lone AN, et al. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. BMJ. 2022. PMID: 35508321. doi:10.1136/bmj-2021-069116

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。